GH Research (GHRS) Stock Price, News & Analysis

Company Overview

GH Research (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for psychiatric disorders. Founded to address significant unmet needs in mental health, the company’s research program focuses on fast-acting treatments that could provide rapid relief for patients suffering from major depressive disorder, post-traumatic stress disorder and other mood-related conditions. GH Research leverages proprietary chemistry and advanced delivery technologies to create a pipeline of next-generation compounds designed to work through unique mechanisms of action.

The company’s lead candidate, GH001, is an inhaled formulation of a differentiated phencyclidine analogue being evaluated for treatment-resistant depression. GH001 is engineered for rapid onset of action and precise dosing, with the goal of reducing the time to therapeutic effect compared to existing therapies. Earlier-stage assets in GH Research’s portfolio include novel ketamine- and MDMA-inspired compounds currently in preclinical development, each targeting distinct neurochemical pathways implicated in mood regulation and stress response.

GH Research maintains its headquarters in Dublin, Ireland, with additional research and development operations in the United Kingdom and the United States. The company collaborates with academic institutions and contract research organizations to conduct its clinical trials and to advance its understanding of psychedelic-inspired medicines. Through these partnerships, GH Research aims to generate robust clinical data that could support expedited pathways to regulatory approval.

Leadership at GH Research is composed of seasoned executives and board members with deep experience in neuroscience, drug development and regulatory affairs. The management team draws on expertise from both large pharmaceutical companies and nimble biotech startups to navigate the complexities of psychiatric drug development. With a commitment to scientific rigor and patient safety, GH Research is positioned to push the boundaries of current treatment paradigms and bring transformative therapies to individuals living with serious mental health disorders.

Key Stats

• Today's Range: $15.25 to $16.13
• 50-Day Range: $9.98 to $16.05
• 52-Week Range: $6.00 to $20.50
• Volume: 146,647 shs
• Average Volume: 197,923 shs
• Market Capitalization: $825.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.00
• Consensus Rating: Buy

GH Research Stock Analysis - MarketRank™

GH Research scored higher than 40% of companies evaluated by MarketBeat, and ranked 685th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

GH Research has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

GH Research has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for GH Research are expected to decrease in the coming year, from ($0.80) to ($1.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GH Research is -20.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GH Research is -20.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GH Research has a P/B Ratio of 4.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.71% of the float of GH Research has been sold short.

Short Interest Ratio / Days to Cover

GH Research has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.

Change versus previous month

Short interest in GH Research has recently decreased by 3.99%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GH Research does not currently pay a dividend.

Dividend Growth

GH Research does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.71% of the float of GH Research has been sold short.

Short Interest Ratio / Days to Cover

GH Research has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.

Change versus previous month

Short interest in GH Research has recently decreased by 3.99%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.35

News Sentiment

GH Research has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for GH Research this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for GHRS on MarketBeat in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GH Research insiders have not sold or bought any company stock.

Percentage Held by Insiders

41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

56.90% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GHRS Stock Analysis - Frequently Asked Questions

How have GHRS shares performed this year?

GH Research's stock was trading at $7.00 on January 1st, 2025. Since then, GHRS stock has increased by 126.7% and is now trading at $15.87.

How were GH Research's earnings last quarter?

GH Research PLC (NASDAQ:GHRS) released its quarterly earnings results on Thursday, May, 8th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.61) by $0.42.

When did GH Research IPO?

GH Research (GHRS) raised $150 million in an initial public offering on Friday, June 25th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

How do I buy shares of GH Research?

Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GH Research own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GH Research investors own include Baidu (BIDU), Shopify (SHOP), Bristol Myers Squibb (BMY), Zoom Communications (ZM), atai Life Sciences (ATAI), CRISPR Therapeutics (CRSP) and Caesars Entertainment (CZR).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 9/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GHRS
• CIK: 1855129
• Web: www.ghres.com
• Phone: 212-450-4000
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for GH Research: $32.00
• High Price Target: $40.00
• Low Price Target: $25.00
• Potential Upside/Downside: +101.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.96 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -19.20%
• Return on Assets: -18.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 29.71
• Quick Ratio: 29.71

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.44 per share
• Price / Book: 4.61

Miscellaneous

• Outstanding Shares: 52,030,000
• Free Float: 30,384,000
• Market Cap: $825.72 million
• Optionable: Optionable
• Beta: 0.96